



June 1, 2016

## Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/01/16 -- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.

The presentation will be webcast live and can be accessed from Innoviva's website at [www.inva.com](http://www.inva.com) or from the following link: <http://wsw.com/webcast/jeff97/inva> a replay of the presentation will be available following the presentation for 90 days.

### **About Innoviva**

Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of biopharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at [www.inva.com](http://www.inva.com).

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)

### **Contact**

Eric d'Esparbes  
Senior Vice President and Chief Financial Officer  
650-238-9640  
[investor.relations@inva.com](mailto:investor.relations@inva.com)

Source: Innoviva

News Provided by Acquire Media